Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how competitive Abecma will continue to be in the multiple myeloma space given an ...
Shares of 2seventy bio, Inc. (NASDAQ:TSVT – Get Free Report) have received a consensus rating of “Hold” from the eight ...
(Reuters) -Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy ...
Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...
Morgan Stanley lowered the firm’s price target on 2seventy Bio (TSVT) to $5 from $6 and keeps an Equal Weight rating on the shares following ...
The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...
Dealbreaker on MSN3d
Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio In $286M DealMultiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...
More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...
The Ademi Firm is investigating 2seventy bio (Nasdaq: TSVT) for possible breaches of fiduciary duty and other violations of ...
Inc. has announced a definitive merger agreement under which BMS will acquire all of the outstanding shares of 2seventy bio.
Cambridge: 2seventy bio, Inc. has announced a definitive merger agreement under which Bristol Myers Squibb will acquire all ...
Abecma made $406 million in 2024, of which BMS paid $43 million to 2seventy bio as part of their profit-sharing agreement.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback